Close the contribution of Viatris's biosimilars portfolio to Biocon Biologics
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 28 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- 29 Nov 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expected to occur in the second half of 2022 subject to satisfaction of closing conditions, including certain regulatory approvals”
What we found
Evidence strength A What the grades mean
A 2023 10-Q states Viatris completed the contribution of its biosimilars portfolio to Biocon Biologics on November 29, 2022, before the December 31, 2022 deadline.
-
A Viatris 10-Q filed 2023-05-08
“On November 29, 2022, Viatris completed a transaction to contribute its biosimilars portfolio to Biocon Biologics.” ✓ confirmed on the page
Market reaction: the shares moved +3.3% against the S&P 500 over the three sessions around the disclosure (5 May 2023 to 10 May 2023). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Transaction other
- Indicative materiality
- Medium rules
- Action
- Close
- Deliverable
- Biocon Biologics biosimilars portfolio transaction
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to satisfaction of closing conditions, including certain regulatory approvals
- Depends on
- Regulatory, Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Viatris? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-VTRS-006562 · Corrections policy